Keywords: fda, review, impax, anda, allegra-d, generic, laboratories
FDA to review IMPAX ANDA for Allegra-D generic
Article | 18 February 2002
IMPAX Laboratories' application to market a generic version ofAventis' antihistamine Allegra-D (fexofenadine HCl plus pseudoephedrine HCl) 60mg/120mg tablets has ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
